Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review
Orbit · 2024
DOI: 10.1080/01676830.2023.2191273 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Orbit, 2024. Verfasst von Fatimah A Alhammad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oculoplastic division, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Conjunctival Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: work featured.
Abstract (Originalsprache)
INTRODUCTION: Conjunctival melanoma (CM) has genetic characteristics that are similar to primary cutaneous melanoma (PCM). The management of advanced CM with orbital metastasis was limited until the adoption of novel immunotherapy agents that significantly improved the survival of metastatic PCM. PURPOSE: To review and compare the immune checkpoint inhibitor (ICI) treatment response in cases reported in the English literature with orbital involvement secondary to CM versus PCM. In addition, we report a case of local recurrence of CM in a young female after successful treatment with ICI. METHODS: In addition to reviewing the chart of one patient who presented to our clinic, we conducted a comprehensive literature review to identify CM cases and cases with orbital metastasis secondary to advanced CM and PCM. Outcomes included patient demographics, response to ICI, and associated adverse effects. RESULTS: There were ten cases with orbital involvement, four were secondary to CM, and six were metastasis from PCM. Orbital metastasis from PCM regressed following treatment with ICI agents, whereas those secondary to CM resolved completely. There were 19 cases of CM without orbital invasion. Of the 29 cases identified, complete resolution of ocular melanoma was achieved in 15 patients, representing 52% of the cases collectively, and none of them reported recurrence except in our case. CONCLUSION: CM with orbital invasion responds well to ICIs, with manageable toxic effects. Despite the complete resolution, close observation is needed as the recurrence risk remains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oculoplastic division, Dhahran Eye Specialist Hospital, Dhahran, Saudi Arabia.
- Ophthalmology Program, Ministry of Health, Riyadh, Saudi Arabia.
- Dammam Regional Laboratory & Blood Bank, Ministry of Health, Riyadh, Saudi Arabia.
- Medical Oncology Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Förderung
- work featured
Zitieren
APA
Alhammad, F. A., Alburayk, K. B., Albadri, K. S., Butt, S. A., & Azam, F. (2024). Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review. Orbit. https://doi.org/10.1080/01676830.2023.2191273
Vancouver
Alhammad FA, Alburayk KB, Albadri KS, Butt SA, Azam F. Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review. Orbit. 2024. doi:10.1080/01676830.2023.2191273
BibTeX
@article{Alhammad2024,
author = {Alhammad, Fatimah A and Alburayk, Khalid B and Albadri, Khadija S and Butt, Sohail A and Azam, Faisal},
title = {Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review},
journal = {Orbit},
year = {2024},
doi = {10.1080/01676830.2023.2191273}
}
EUVIMED